Jnana Therapeutics Inc. has synthesized sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of amino acid metabolism disorders, amino acid transport disorders and metabolic and nutritional genetic disorders, among others.
Cullgen (Shanghai) Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a DDB1- and CUL4-associated factor 1 (DCAF1) binding moiety covalently linked to target protein moiety (such as bromodomain-containing protein 4 [BRD4; HUNK1], cyclin-dependent kinase 4 [CDK4] and estrogen receptor α [ER-α; ESR1]) through a linker reported to be useful for the treatment of cancer.
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with poor prognosis and limited therapeutic options, and it accounts for 15%-20% of female invasive breast cancers.
Researchers from Beijing Pharscin Innobio Co. Ltd. presented the discovery and preclinical characterization of a novel highly selective poly (ADP-ribose) polymerase 7 (PARP7) inhibitor, HSN-002066, being developed for the treatment of cancer.
The U.S. FDA has cleared Tr1x Inc.’s IND application for TRX-103 for the prevention of graft-vs.-host disease (GVHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT).
The overexpression of transferrin receptor 1 (TfR1) has been reported in several cancer types but is also expressed in normal cell types such as erythroblasts. On the other hand, epidermal growth factor receptor (EGFR) is highly expressed in epithelial carcinomas.
Cereno Scientific AB has submitted a clinical trial application (CTA) to the EMA seeking approval for a first-in-human, phase I study of CS-014, a novel histone deacetylase (HDAC) inhibitor drug candidate under development as an antithrombotic treatment.
Sitryx Therapeutics Ltd. has nominated SYX-5219 as the first candidate from its proprietary pipeline to progress to regulatory nonclinical studies to support a clinical trial authorization (CTA). SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis.
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord blood-derived NK cells that were genetically modified to express CD5-directed CAR and simultaneously produce IL-15 to support NK cell survival and proliferation.
RSS
